Euglycemic Diabetic Ketoacidosis in a Lung Cancer Patient Using Empagliflozin
Joint Authors
Sexe, Jordan
Mayes, Chadwick
Tofts, Peter
Source
Issue
Vol. 2020, Issue 2020 (31 Dec. 2020), pp.1-3, 3 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2020-07-01
Country of Publication
Egypt
No. of Pages
3
Main Subjects
Abstract EN
Diabetic ketoacidosis is a leading cause of morbidity and mortality in diabetic patients, and its diagnosis should be timely and accurate.
SGLT2 inhibitors are a new class of antidiabetic medications that increase the renal excretion of glucose.
It is thought that increased urinary excretion of glucose will mask hyperglycemia during DKA.
This can lead to a delayed diagnosis of DKA and worsen outcomes.
In this report, we detail a case of euglycemic DKA in a patient who presented to the Emergency Department meeting criteria for septic shock.
American Psychological Association (APA)
Sexe, Jordan& Mayes, Chadwick& Tofts, Peter. 2020. Euglycemic Diabetic Ketoacidosis in a Lung Cancer Patient Using Empagliflozin. Case Reports in Critical Care،Vol. 2020, no. 2020, pp.1-3.
https://search.emarefa.net/detail/BIM-1146295
Modern Language Association (MLA)
Sexe, Jordan…[et al.]. Euglycemic Diabetic Ketoacidosis in a Lung Cancer Patient Using Empagliflozin. Case Reports in Critical Care No. 2020 (2020), pp.1-3.
https://search.emarefa.net/detail/BIM-1146295
American Medical Association (AMA)
Sexe, Jordan& Mayes, Chadwick& Tofts, Peter. Euglycemic Diabetic Ketoacidosis in a Lung Cancer Patient Using Empagliflozin. Case Reports in Critical Care. 2020. Vol. 2020, no. 2020, pp.1-3.
https://search.emarefa.net/detail/BIM-1146295
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1146295